BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36930848)

  • 1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
    Burgos L; Tamariz-Amador LE; Puig N; Cedena MT; Guerrero C; Jelínek T; Johnson S; Milani P; Cordon L; Perez JJ; Lasa M; Termini R; Oriol A; Hernandez MT; Palomera L; Martinez-Martinez R; de la Rubia J; de Arriba F; Rios R; Gonzalez ME; Gironella M; Cabañas V; Casanova M; Krsnik I; Perez-Montaña A; González-Calle V; Rodriguez-Otero P; Maisnar V; Hajek R; Van Rhee F; Jimenez-Zepeda V; Palladini G; Merlini G; Orfao A; de la Cruz J; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B;
    J Clin Oncol; 2023 Jun; 41(16):3019-3031. PubMed ID: 36930848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
    Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
    Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
    Fend F; Dogan A; Cook JR
    Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When a Monoclonal Gammopathy Is Not Multiple Myeloma.
    Derman B; Castillo JJ; Sarosiek S; Beksac M
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35394823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.
    Leung N; Bridoux F; Hutchison CA; Nasr SH; Cockwell P; Fermand JP; Dispenzieri A; Song KW; Kyle RA;
    Blood; 2012 Nov; 120(22):4292-5. PubMed ID: 23047823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [AL amyloidosis presenting with fluminant multiorgan failure accompanied by rapid progression from MGUS to multiple myeloma].
    Tazoe K; Takakuwa T; Makuuchi Y; Kuno M; Harada N; Okamura H; Nishimoto M; Koh H; Nakashima Y; Nakamae H; Hino M
    Rinsho Ketsueki; 2022; 63(1):31-36. PubMed ID: 35135949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal gammopathy of (un)known significance].
    Steinhardt M; Kortüm M; Einsele H; Rasche L
    Dtsch Med Wochenschr; 2022 Jun; 147(11):675-682. PubMed ID: 35636418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Skin disorders associated with monoclonal gammopathies].
    Houtman CJ; Genders RE; von dem Borne PA; Vermeer MH
    Ned Tijdschr Geneeskd; 2014; 158():A6717. PubMed ID: 24780569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal Gammopathy of Undetermined Significance.
    Gonsalves WI; Rajkumar SV
    Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.